Phase II study in stage II-III triple-negative breast cancer (22 enrolled, 14 had FDG-PET): falls in FDG uptake after one neoadjuvant chemotherapy cycle correlated with mid-treatment MRI response and residual cancer burden at surgery.
RCTn = 22
Akay et al. A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer